Exelixis (EXEL) Slides as Investors Likely Take Profits Ahead of Earnings

Exelixis, Inc. (EXEL) is down 5.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a mix of profit-taking and caution ahead of the company’s August 5 second-quarter results, rather than a fresh company-specific shock. Sentiment may also still be tempered by June clinical data that showed a favorable trend in a key colorectal cancer subgroup but did not reach statistical significance, leaving some uncertainty around the longer-term pipeline story.

Details:

Exelixis’ investor calendar shows its next major event is the second-quarter 2026 earnings release and conference call on August 5, which can pressure biotech shares as traders reduce risk ahead of results.

The company’s most recent major pipeline update in late June said the STELLAR-303 subgroup analysis showed a non-statistically significant overall survival trend for zanzalintinib plus atezolizumab in patients without active liver metastases.

Recent analyst actions remained cautious, with several firms maintaining hold or equal-weight style ratings and price targets that were not far above, and in some cases below, where the stock had recently traded.

Shares had also climbed to a record high in July, so a sharp one-day pullback can reasonably reflect valuation discipline and short-term profit-taking after a strong run.

Sources:

Exelixis, Google Finance, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$EXEL Insider Trading Activity

$EXEL insiders have traded $EXEL stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.

Here’s a breakdown of recent trading of $EXEL stock by insiders over the last 6 months:

DANA AFTAB (EVP, Research and Development) has made 0 purchases and 3 sales selling 121,242 shares for an estimated $5,644,976.
JULIE SMITH has made 0 purchases and 3 sales selling 106,539 shares for an estimated $4,687,345.
JACK L WYSZOMIERSKI has made 0 purchases and 2 sales selling 103,499 shares for an estimated $4,580,660.
CHRISTOPHER J. SENNER (EVP and CFO) has made 0 purchases and 3 sales selling 99,796 shares for an estimated $4,556,048.
PATRICK J. HALEY (EVP, Commercial) has made 0 purchases and 2 sales selling 67,814 shares for an estimated $2,950,941.
BOB OLIVER has made 0 purchases and 2 sales selling 30,250 shares for an estimated $1,325,339.
BRENDA HEFTI (SVP and General Counsel) has made 0 purchases and 2 sales selling 25,294 shares for an estimated $1,154,263.
SUE GAIL ECKHARDT has made 0 purchases and 2 sales selling 13,668 shares for an estimated $660,827.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$EXEL Hedge Fund Activity

We have seen 334 institutional investors add shares of $EXEL stock to their portfolio, and 336 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FARALLON CAPITAL MANAGEMENT LLC removed 2,598,490 shares (-16.5%) from their portfolio in Q1 2026, for an estimated $111,449,236
TWO SIGMA INVESTMENTS, LP added 1,932,421 shares (+705.8%) to their portfolio in Q1 2026, for an estimated $82,881,536
NUVEEN, LLC added 1,351,251 shares (+55.6%) to their portfolio in Q1 2026, for an estimated $57,955,155
QUBE RESEARCH & TECHNOLOGIES LTD removed 1,337,603 shares (-99.5%) from their portfolio in Q1 2026, for an estimated $57,369,792
UBS GROUP AG removed 1,328,821 shares (-35.7%) from their portfolio in Q1 2026, for an estimated $56,993,132
JUPITER ASSET MANAGEMENT LTD removed 1,070,289 shares (-52.5%) from their portfolio in Q1 2026, for an estimated $45,904,695
FIRST TRUST ADVISORS LP added 970,144 shares (+62.0%) to their portfolio in Q1 2026, for an estimated $41,609,476

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$EXEL Analyst Ratings

Wall Street analysts have issued reports on $EXEL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/12/2026

To track analyst ratings and price targets for $EXEL, check out Quiver Quantitative's $EXEL forecast page.

$EXEL Price Targets

Multiple analysts have issued price targets for $EXEL recently. We have seen 10 analysts offer price targets for $EXEL in the last 6 months, with a median target of $51.0.

Here are some recent targets:

Gregory Renza from Truist Securities set a target price of $56.0 on 07/07/2026
Leonid Timashev from RBC Capital set a target price of $46.0 on 07/07/2026
Robert Burns from HC Wainwright & Co. set a target price of $56.0 on 07/02/2026
Ashwani Verma from UBS set a target price of $52.0 on 07/02/2026
Silvan Turkcan from Citizens set a target price of $55.0 on 06/24/2026
Stephen Willey from Stifel set a target price of $47.0 on 05/06/2026
Yaron Werber from TD Cowen set a target price of $55.0 on 05/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.